CPX-351 and Ivosidenib for Leukemia Treatment
Phase 2
30
about 5.4 years
18+
1 site in TX
What this study is about
This trial is testing a treatment with CPX-351 and ivosidenib to see if it helps people with acute myeloid leukemia or high-risk myelodysplastic syndrome that has an IDH1 mutation. The goal is also to learn about the safety of this combination.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Ivosidenib
- 2.Take Liposome-encapsulated Daunorubicin-Cytarabine
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
ivosidenib
oral (Oral Tablet), injection (Injection)
Primary: Overall response rate (ORR)
Secondary: Duration of response, Event-free survival, Incidence of adverse events, Overall survival
Oncology